Selected studies assessing outcomes of patient who received therapy for MCL after relapsing while treated with BTKi
| Treatment . | Reference . | Study . | N . | Median age, y . | High risk* . | Median prior lines therapy . | Response to prior BTKi . | Response to treatment . | Transplant consolidation . | Outcomes, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| Assorted (lenalidomide 26%, cytarabine 18%, bendamustine 16%, bortezomib 10%) | 54 | Retrospective multicenter† | 73 | 67 | 48% | 4 (1-11) | ORR 50% CR 11%; median DOI 4.7 m | ORR 26% CR 7% | 5 (6.8%) | Median OS 5.8 |
| Lenalidomide ± anti-CD20 ± chemotherapy | 67 | Observational multicenter‡ | 58 | 71 | NA | 4 (1-13) | ORR 45% CR 14%; median DOI 4.3 mo | ORR 29% CR 14% | NA | Median DOR 5 |
| Venetoclax monotherapy | 68 | Retrospective multicenter | 20 | 69 | 55% | 3 (2-5) | ORR 55% CR 15% median DOI 4.8 mo | ORR 53% CR 18% | 1 (5.0%) | Median PFS 3.2; median OS 9.4 |
| Venetoclax monotherapy | 69 | Retrospective single center | 24§ | 69 | 67% | 5 (1-11) | “66% BTKi resistant” | ORR 50% CR 21% | — | Median PFS 8; median OS 13.5 |
| R-BAC | 71 | Retrospective multicenter | 36 | 66 | 58% | 2 (1-6) | ORR 68% CR 32%; median PFS 9.2 mo | ORR 83% CR 60% | 12 (33.3%) | Median PFS 10.1; median OS 12.5 |
| Brexucabtagene autoleucel | 77 | Phase 2 | 74 | 65 | NA | 3 (1-5) | ORR 38% | ORR 93% CR 67% | — | 1-y PFS 61% 1-y OS 83% |
| Lisocabtagene maraleucel | 53 | Phase 1 | 41 | 67 | NA | 3 (1-7) | ORR 66% | ORR 84% CR 59% | — | NA |
| Pirtobrutinib | 85 | Phase 1/2 | 61 | 69 | NA | 3 (2-4) | NA | ORR 52% CR 25% | NA | NA |
| Zilovertamab vedotin | 86 | Phase 1 | 15 | 70ǁ | NA | 4 (1-24)ǁ | NA | ORR 47% CR 13% | NA | NA |
| Treatment . | Reference . | Study . | N . | Median age, y . | High risk* . | Median prior lines therapy . | Response to prior BTKi . | Response to treatment . | Transplant consolidation . | Outcomes, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| Assorted (lenalidomide 26%, cytarabine 18%, bendamustine 16%, bortezomib 10%) | 54 | Retrospective multicenter† | 73 | 67 | 48% | 4 (1-11) | ORR 50% CR 11%; median DOI 4.7 m | ORR 26% CR 7% | 5 (6.8%) | Median OS 5.8 |
| Lenalidomide ± anti-CD20 ± chemotherapy | 67 | Observational multicenter‡ | 58 | 71 | NA | 4 (1-13) | ORR 45% CR 14%; median DOI 4.3 mo | ORR 29% CR 14% | NA | Median DOR 5 |
| Venetoclax monotherapy | 68 | Retrospective multicenter | 20 | 69 | 55% | 3 (2-5) | ORR 55% CR 15% median DOI 4.8 mo | ORR 53% CR 18% | 1 (5.0%) | Median PFS 3.2; median OS 9.4 |
| Venetoclax monotherapy | 69 | Retrospective single center | 24§ | 69 | 67% | 5 (1-11) | “66% BTKi resistant” | ORR 50% CR 21% | — | Median PFS 8; median OS 13.5 |
| R-BAC | 71 | Retrospective multicenter | 36 | 66 | 58% | 2 (1-6) | ORR 68% CR 32%; median PFS 9.2 mo | ORR 83% CR 60% | 12 (33.3%) | Median PFS 10.1; median OS 12.5 |
| Brexucabtagene autoleucel | 77 | Phase 2 | 74 | 65 | NA | 3 (1-5) | ORR 38% | ORR 93% CR 67% | — | 1-y PFS 61% 1-y OS 83% |
| Lisocabtagene maraleucel | 53 | Phase 1 | 41 | 67 | NA | 3 (1-7) | ORR 66% | ORR 84% CR 59% | — | NA |
| Pirtobrutinib | 85 | Phase 1/2 | 61 | 69 | NA | 3 (2-4) | NA | ORR 52% CR 25% | NA | NA |
| Zilovertamab vedotin | 86 | Phase 1 | 15 | 70ǁ | NA | 4 (1-24)ǁ | NA | ORR 47% CR 13% | NA | NA |
DOI, duration of ibrutinib; DOR, duration of response; NA, not available.
Defined by Mantle cell lymphoma international prognostic index (MIPI) or sMIPI (simplified MIPI).
Survival time taken from date of last ibrutinib treatment, not the start of the next-line therapy.
All but 1 patient enrolled retrospectively.
22/24 BTKi exposed.
For all patients in the study; MCL subset was not reported separately.